MKI67 and breast cancer: These findings, overall, might suggest that the ability of metformin to target the relationship between lowered Ki67 and inhibition of tumor growth could occur in the absence of objective tumor regression and likely involves pathobiological features of post-therapy residual BC disease that are different to treatment-naïve BC.